Canadian consensus conference: The FDA decision on the use of 5ARIs

Journal of the Canadian Urological Association

Volumn 6, Issue 2, 2012, Pages 83-88

  Klotz, Laurence ^a   Chetner, Michael ^b   Chin, Joseph ^c   Finelli, Tony ^d   Fleshner, Neil ^e   Fradet, Yves ^f   Goldenberg, Larry ^g   Curtis Nickel, J ^h   Siemens, Robert ^h   So, Alan ^g   Sugar, Linda ⁱ   Zlotta, Alexandre ^a   Klein, Eric ^j   Parnes, Howard ^k   Penson, David ^l  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f UNIVERSITÉ LAVAL   (Canada)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h QUEEN S UNIVERSITY   (Canada)

ⁱ SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^j Glickman Urological and Kidney Institute   (Canada)

^k NATIONAL CANCER INSTITUTE   (United States)

^l VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84859984307     PISSN: 19116470     EISSN: None     Source Type: Journal    
DOI: 10.5489/cuaj.12058     Document Type: Article

References (11)

1. U.S. Food and Drug Administration. December 1, 2010: Oncologic Drugs Advisory Committee Meeting Announcement. Available online at: http://www.fda.gov/AdvisoryCommittees/Calendar/ucm230653.htm. Accessed on March 22, 2012.
2. Croker KS, Ryan A, Morzenti T, et-al. Delivering prostate cancer prevention messages to the public: How the National Cancer Institute (NCI) effectively spread the word about prostate cancer prevention trial (PCPT) results. Urol Oncol 2004;22:369-76.
3. Andriole GL, Bostwick DG, Brawley OW, et al; REDUCE Study Group. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192-202.
4. Andriole GL, Bostwick DG, Brawley OW, et al; REDUCE Study Group. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol 2011;185:126-31.
5. Lotan Y, Cadeddu JA, Lee JJ, et al. Implications of the prostate cancer prevention trial: a decision analysis of survival outcomes. J Clin Oncol 2005;20:1911-20.
6. Theoret MR, Yang-Min N, Zhang JJ, et al. The risks and benefits of 5a-reductase inhibitors for prostatecancer prevention. N Engl J Med 2011;365:97-9.
7. Thompson IM, Pauler, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per millimeter. N Engl J Med 2004;350:2239-46.
8. Thompson IM, Goodman PJ, Tanger CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
9. Unger J, Thompson IM, LeBlanc, et al. Estimated impact of the Prostate Cancer Prevention trial on population mortality. Cancer 2005;103:1375-80.
10. Epstein, Jonathan I, Allsbrook, et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005;29:1228-42.
11. U.S. Preventive Services Task Force (UPSTF). Screening for prostate cancer: A review of the evidence for the U.S. Preventive Task Force. Available at: http://www.annals.org/content/early/2011/10/07/0003-4819-155-11-201112060-00375.1.fullabout:Tabs. Last accessed on March 22, 2012.